- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06001918
Klinische studie Nectero EAST-systeem (stAAAble)
Gerandomiseerde gecontroleerde klinische studie (RCT) van het Nectero EAST-systeem voor stabilisatie van kleine tot middelgrote abdominale aorta-aneurysma's (AAA): evaluatie van de werkzaamheid.
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed at designated intervals at 30/60 days, 6, 12, 18 and 24 months with continued follow-up annually for up to 5 years.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Charlene Knape
- Telefoonnummer: 866-755-4744
- E-mail: cknape@necteromedical.com
Studie Contact Back-up
- Naam: Tracy Roberts
- Telefoonnummer: (303)3964603
- E-mail: troberts@necteromedical.com
Studie Locaties
-
-
New South Wales
-
Randwick, New South Wales, Australië, 2031
- Werving
- Prince of Wales Private Hospital- POW Vascular Institute
-
Hoofdonderzoeker:
- Ramon Varcoe
-
Contact:
- Jade Goh
- Telefoonnummer: 04 87 369 396
- E-mail: pow.vascular.institute@gmail.com
-
-
-
-
-
Auckland, Nieuw-Zeeland, 1023
- Werving
- Auckland City Hospital
-
Contact:
- Cynthia Corne
- Telefoonnummer: 21505 +64 9 307 4949
- E-mail: CorneC@adhb.govt.nz
-
Hoofdonderzoeker:
- Andrew Holden, A/Prof
-
-
-
-
Arizona
-
Scottsdale, Arizona, Verenigde Staten, 85258
- Werving
- Honor Health Scottsdale Shea Medical Center
-
Hoofdonderzoeker:
- Hasan Aldailami, MD
-
Contact:
- HonorHealth Cardiovascular Research
- Telefoonnummer: 480-323-1046
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Actief, niet wervend
- University of Colorado
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20010
- Werving
- Medstar Washington Hospital Center
-
Hoofdonderzoeker:
- Steven Abramowitz, MD
-
Contact:
- Kassaye Sesaba, MD
- Telefoonnummer: 202-877-7452
- E-mail: Kassaye.T.Sesaba@medstar.net
-
Contact:
- Suman Singh, MD
- Telefoonnummer: (202) 877-8475
- E-mail: Suman.Singh@Medstar.net
-
-
Florida
-
Delray Beach, Florida, Verenigde Staten, 33446
- Werving
- Prime Vascular Institute
-
Hoofdonderzoeker:
- Joseph Ricotta, MD
-
Contact:
- Jordan Sprechman
- Telefoonnummer: 561-495-3145
- E-mail: Jordan.Sprechman@tenethealth.com
-
Contact:
- Alexia Medick
- E-mail: Alexia.Medick@tenethealth.com
-
-
Georgia
-
Augusta, Georgia, Verenigde Staten, 30912
- Werving
- Medical College of Georgia
-
Hoofdonderzoeker:
- William Jordan, MD
-
Contact:
- Natasha Flores
- E-mail: nflores@augusta.edu
-
Contact:
- Candelario Laserna
- Telefoonnummer: 706-721-2199
- E-mail: calaserna@augusta.edu
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago
-
Contact:
- MacKenton Johnson
- Telefoonnummer: 773-795-3639
- E-mail: mackenton@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Ross Milner, MD
-
Elk Grove, Illinois, Verenigde Staten, 60007
- Nog niet aan het werven
- Ascension Alexian Brothers
-
Hoofdonderzoeker:
- Jack Chamberlin, MD
-
-
Maine
-
Scarborough, Maine, Verenigde Staten, 04074
- Werving
- MaineMed Vascular Surgery
-
Hoofdonderzoeker:
- Kristina Giles, MD
-
Contact:
- Kathryn Ackermann
- E-mail: kathryn.ackermann@mainehealth.org
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Massachusetts General Hospital
-
Hoofdonderzoeker:
- Nikolaos Zacharias, MD
-
Contact:
- Bonnie Chen
- E-mail: BCHEN13@mgh.harvard.edu
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Beth Israel Deaconess Medical Center
-
Hoofdonderzoeker:
- Marc Schermerhorn, MD
-
Contact:
- Monica Goyal
- Telefoonnummer: 617-632-7534
- E-mail: mgoyal@bidmc.harvard.edu
-
Contact:
- Fernando Moreno
- E-mail: fmoreno@bidmc.harvard.edu
-
Worcester, Massachusetts, Verenigde Staten, 01655
- Werving
- University of Massachusetts
-
Contact:
- Shauneen Valliere
- E-mail: shauneen.valliere@umassmed.edu
-
Hoofdonderzoeker:
- Andres Schanzer, MD
-
-
Michigan
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Werving
- Beaumont Health
-
Hoofdonderzoeker:
- Graham Long, MD
-
Contact:
- Lisa Bliss
- E-mail: lisa.bliss@corewellhealth.org
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Washington University School of Medicine
-
Hoofdonderzoeker:
- Luis Sanchez, MD
-
Contact:
- Briana K Langrehr, BSN
- E-mail: briana.l@wustl.edu
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68198
- Werving
- University of Nebraska Medical Center
-
Hoofdonderzoeker:
- Jonathan Thompson, MD
-
Contact:
- Jarod Phillips
- E-mail: jarphillips@unmc.edu
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03766
- Werving
- Dartmouth Hitchcock Medical Center
-
Hoofdonderzoeker:
- Rebecca Scully, MD
-
Contact:
- Pauline Sirrell
- E-mail: pauline.sirrell@hitchcock.org
-
-
New York
-
Rochester, New York, Verenigde Staten, 14642
- Werving
- University of Rochester
-
Contact:
- Mary Bourret
- E-mail: Mary_Bourret@URMC.Rochester.edu
-
Hoofdonderzoeker:
- Doran Mix, MD
-
Stony Brook, New York, Verenigde Staten, 11794
- Nog niet aan het werven
- Stony Brook Medicine
-
Hoofdonderzoeker:
- Rabih Chaer, MD
-
Contact:
- Daria Shavarina
- E-mail: Daria.Shavarina@stonybrookmedicine.edu
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke University Medical Center
-
Hoofdonderzoeker:
- Chandler Long, MD
-
Contact:
- Ellen Burkett
- Telefoonnummer: (919)681-1878
- E-mail: ellen.jones@duke.edu
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Werving
- The Christ Hospital
-
Contact:
- Jamie Elkins
- E-mail: Jamie.Elkins@thechristhospital.com
-
Hoofdonderzoeker:
- Geoff Answini, MD
-
Cleveland, Ohio, Verenigde Staten, 44106
- Werving
- University Hospitals Cleveland
-
Hoofdonderzoeker:
- Jae Cho, MD
-
Contact:
- Amy Kluge
- E-mail: Amy.Kluge@UHhospitals.org
-
Cleveland, Ohio, Verenigde Staten, 44195
- Werving
- Cleveland Clinic
-
Hoofdonderzoeker:
- Francis Caputo, MD
-
Contact:
- Laurie Ann Moennich
- E-mail: MOENNIL@ccf.org
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- The Ohio State University Wexner Medical Center
-
Contact:
- Subh Das
- Telefoonnummer: 614-366-6596
- E-mail: subhashish.das@osumc.edu
-
Hoofdonderzoeker:
- Kristine Orion, MD
-
Columbus, Ohio, Verenigde Staten, 43214
- Werving
- Ohio Health Riverside
-
Hoofdonderzoeker:
- Joseph Campbell, MD
-
Contact:
- Regan Moran
- E-mail: Regan.Moran@ohiohealth.com
-
-
Oklahoma
-
Tulsa, Oklahoma, Verenigde Staten, 74104
- Werving
- Oklahoma Heart Institute
-
Hoofdonderzoeker:
- Julia Chen, MD
-
Contact:
- Tia Whitaker
- E-mail: Tia.Whitaker@hillcrest.com
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Werving
- Portland VA Medical Center
-
Hoofdonderzoeker:
- Matthew Koopmann, MD
-
Contact:
- Rachel Nelson
- E-mail: Rachel.Nelson1@va.gov
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Verenigde Staten, 18015
- Werving
- St. Luke's University Health Network
-
Hoofdonderzoeker:
- Sharvil Sheth, MD
-
Contact:
- Jena Hagerty
- Telefoonnummer: 484-658-4982
- E-mail: Jena.Hagerty@sluhn.org
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Hospital of the University of Pennsylvania
-
Contact:
- Carolina Reyes
- Telefoonnummer: 215-615-8036
- E-mail: carolina.reyes1@pennmedicine.upenn.edu
-
Hoofdonderzoeker:
- Grace Wang, MD
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Werving
- Jefferson Clinical Research Institute
-
Contact:
- Jona Shperdheja
- E-mail: Jona.Shperdheja@jefferson.edu
-
Hoofdonderzoeker:
- Michael Nooromid, MD
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15219
- Werving
- University of Pittsburgh Medical Center
-
Contact:
- Judith Brimmeier
- E-mail: brimmeierja@upmc.edu
-
Hoofdonderzoeker:
- Raymond Eid, MD
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29605
- Werving
- Prisma Health
-
Hoofdonderzoeker:
- Mark P Androes, MD
-
Contact:
- Nikita Kasinger
- E-mail: Nikita.Kasinger@PrismaHealth.org
-
Contact:
- Maggie Salle
- E-mail: Margaret.Salle@PrismaHealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57108
- Werving
- North Central Heart - A Division of Avera Heart Hospital
-
Hoofdonderzoeker:
- Michael Bacharach, MD
-
Contact:
- Patty Eisenbraun, RN
- Telefoonnummer: 605-977-5336
- E-mail: peisenbraun@ncheart.com
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37232
- Werving
- Vanderbilt University Medical Center
-
Hoofdonderzoeker:
- John Curci, MD
-
Contact:
- Celia Nunez
- E-mail: celia.m.nunez@vumc.org
-
Contact:
- Jennifer Scott
- E-mail: jennifer.scott@vumc.org
-
Nashville, Tennessee, Verenigde Staten, 37212
- Nog niet aan het werven
- VA Tennessee Valley Healthcare System
-
Hoofdonderzoeker:
- John Curci, MD
-
Contact:
- Sohpia Miner
- E-mail: Sophia.Miner@va.gov
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77004
- Werving
- Houston Healthcare
-
Hoofdonderzoeker:
- Kristofer Charlton-Ouw, MD
-
Contact:
- Swathi Potla
- E-mail: swathi.potla@hcahealthcare.com
-
Plano, Texas, Verenigde Staten, 75093
- Werving
- Baylor Scott & White Medical Center
-
Hoofdonderzoeker:
- William Shutze, MD
-
Contact:
- Saba Arianpour
- E-mail: Saba.Arianpour@BSWHealth.org
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84132
- Werving
- University of Utah Hospital
-
Contact:
- Julie Hales
- E-mail: Julie.Hales@hsc.utah.edu
-
Hoofdonderzoeker:
- Cali Johnson, MD
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- Inova Fairfax Medical Campus Inova Health Systems
-
Contact:
- Bhruga Shah
- E-mail: Bhruga.shah@inova.org
-
Hoofdonderzoeker:
- Kendal Endicott, MD
-
Norfolk, Virginia, Verenigde Staten, 23507
- Werving
- Sentara Health
-
Hoofdonderzoeker:
- David Dexter, MD
-
Contact:
- Angela Zahn
- E-mail: AXZAHN@sentara.com
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- Werving
- University of Washington at Harborview Medical Center
-
Contact:
- Allison Larimore
- E-mail: alari@uw.edu
-
Hoofdonderzoeker:
- Benjamin Starnes, MD
-
-
Wisconsin
-
Green Bay, Wisconsin, Verenigde Staten, 54301
- Werving
- Bellin Memorial Hospital
-
Hoofdonderzoeker:
- Jason Ricci, MD
-
Contact:
- Katie Guilliams
- E-mail: Katherine.Guilliams@emplifyhealth.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Males and females ≥21 to ≤85 years of age. Females must be of non-childbearing potential (menopause or sterilization).
- Subject understands the purpose of the trial, agrees to voluntarily participate in the trial, signs the informed consent and is willing to complete the follow-up according to the requirements of the protocol.
- Infrarenal atherosclerotic fusiform abdominal aortic aneurysm from 3.5 cm to 5.0 cm (male) and 3.5 cm to 4.5 cm (female).
- Infrarenal aortic neck ≥ 15 mm in length and ≤ 29 mm in diameter.
- Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 130 mm.
- Iliac and femoral artery access, vessel size and morphology allow endovascular access of 14F (or larger) introducer sheaths and catheters.
- Subject meets American Society of Anesthesiology (ASA) grade 1 through 3 criteria, inclusive.
- Subject has > three-year life expectancy.
- Subject is able and willing to comply with all required follow-up clinic visits including CT scans (pre-randomization, 6, 12, 18, 24 months and annually up to 5 years) and blood draws.
Exclusion Criteria:
- Subject has an acutely ruptured, leaking, dissecting or emergent aneurysm.
- Subject has a symptomatic infrarenal abdominal aortic aneurysm.
- Subject has a mycotic or infected aneurysm.
- Subject has current vascular injury due to trauma.
- Subject's aneurysm is thoracic, suprarenal or juxtarenal.
- Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.
- Subject has anatomy of diffuse, ulcerated, or extensive (shaggy) thrombus in the neck of the AAA, that in the opinion of the vascular surgeon/investigator, could result in embolization of the thrombus.
- Subject has anatomy of calcification, and/or plaque within the ilio-femoral arteries or severe infrarenal neck angulation that may compromise or does not allow delivery of the Introducer Sheath or the delivery catheter of the Nectero EAST System.
- Subject has had a myocardial infarction within six (6) months prior to enrollment or elevated CK enzymes or troponin indicative of an evolving MI prior to procedure.
- Subject has current angina, unstable angina, or other active cardiac condition such as congestive heart failure III and IV, atrial arrhythmia, ventricular arrhythmia, or valvular disease, requiring intervention.
- Subject has undergone other major surgery within the 30 days prior to enrollment.
- Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months.
- Known allergy to contrast material that cannot be adequately premedicated, delivery system materials (i.e., nylon, polyurethane) and/or pentagalloylglucose (PGG).
- Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
- Subject has connective tissue/collagen disorder (e.g., Marfan syndrome, vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Eaton Syndrome, Bessel-Hagen disease, etc.).
- Known contraindication to undergoing angiography or receiving systemic anticoagulation during the procedure.
- Subject has active systemic infection.
- Subject is participating in another research trial that could interfere with the results of the trial (e.g., drug trial).
- Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from participation in the trial and to undergo the procedures and evaluations pre- and post-treatment.
- Subject has dialysis dependent renal failure or baseline serum creatinine level >2.5mg/dL or eGFR < 45 mL/min/1.73m2.
- Subjects with aminotransferase (ALT and/or AST) which is ≥1.5x upper limit of normal (ULN) or TB that is our of normal range for the evaluating laboratory.
- Subjects that may not tolerate the lowering of their systolic blood pressure to approximately 100mmHg, should not be considered for this study or treated using the Nectero EAST System.
- Subjects that may not be able to tolerate transient occlusion of the aorta should not be considered for this study.
- Subjects with saccular AAA.
- Subjects with rapidly expanding AAA (previous diameter increases of ≥0.5 cm in 6-months or ≥1 cm in 1 year) as these should be evaluated for immediate repair.
- Subjects who are not suitable for the Nectero EAST System treatment, as determined by the investigator.
- Subjects with INR out of normal range for the evaluating laboratory for a subject not on anti-coagulant therapy; or INR >3 for a subject on anti-coagulant therapy.
- Subjects with active/acute or a history of unstable chronic liver disease or current liver disease including but not limited to liver transplant, known genetic disorders such as Gilbert syndrome or other liver diseases.
- Subjects with cirrhosis (e.g., known history or new clinical diagnosis by elastography with a fibrosis score of F3 or F4 and/or steatosis grade of S3).
- Subjects with uncontrolled alcohol use disorder or current alcohol use putting them at risk of liver disease: including consumption of above one standard drink per day for women and two standard drinks per day for men.
- Subjects with known right-sided heart failure or pathologically dilated inferior vena cava or hepatic veins indicative of congestive hepatopathy.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment Arm
Participants assigned to the treatment arm will undergo an endovascular procedure using the Nectero EAST System to deliver the Stabilizer Infusion Solution directly inside the aneurysm. This is a one-time local delivery of the product. Following treatment, surveillance of their AAA will be conducted using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years. Intervention: Drug: Stabilizer |
Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug. |
|
Geen tussenkomst: Control Arm
Participants assigned to the control arm will undergo surveillance of their AAA using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Primary Endpoint
Tijdsspanne: 24 months
|
The primary endpoint is the composite of all AAA-related death, rupture and repair (open-surgical, EVAR, or clinically indicated for repair as adjudicated by a committee of clinical experts blinded to the assigned arm). |
24 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Growth
Tijdsspanne: 24 months
|
The growth over time in aneurysm diameter based on CT core laboratory readings. |
24 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Daniel Clair, MD, Vanderbilt University Medical Center
- Hoofdonderzoeker: Grace Wang, MD, University of Pennsylvania
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- EAST002
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .